Literature DB >> 12657850

Optimal adrenergic support in septic shock due to peritonitis.

Qinghua Sun1, Zizhi Tu, Suzana Lobo, George Dimopoulos, Nathalie Nagy, Peter Rogiers, Daniel De Backer, Jean-Louis Vincent.   

Abstract

BACKGROUND: The authors evaluated optimal adrenergic support using norepinephrine, dopamine, and dobutamine in a clinically relevant model of septic shock.
METHODS: Twenty-eight mature, female, anesthetized sheep (weight, 30.5 +/- 3.6 kg) underwent cecal ligation and perforation and were randomized into four groups of seven animals to be treated with norepinephrine, dopamine-norepinephrine, dobutamine-norepinephrine, or no adrenergic agent. In all groups, lactated Ringer's solution was administered to restore cardiac filling pressures to baseline. In the norepinephrine group, norepinephrine (0.5-5 microg. kg(-1). min(-1)) was titrated to maintain mean arterial pressure between 75-85 mmHg. In the dopamine-norepinephrine group, dopamine was given first, and norepinephrine was added only when mean arterial pressure remained below 75 mmHg despite the infusion of 20 microg. kg(-1). min(-1) dopamine. In the dobutamine-norepinephrine group, dobutamine was started at the same time as norepinephrine and titrated up to 20 microg. kg(-1). min(-1) to get a 15% increase in cardiac output.
RESULTS: The dobutamine-norepinephrine group had greater cardiac output; superior mesenteric blood flow, oxygen delivery (Do(2)), and oxygen consumption ([OV0312]o(2)); and lower blood lactate concentration and partial pressure of carbon dioxide (Pco(2)) gap than the controls did. Cumulative urine output was significantly higher in the dobutamine-norepinephrine group than in the other groups. Survival time was significantly longer in the dobutamine-norepinephrine (24 +/- 4 h), dopamine- norepinephrine (24 +/- 6 h), and norepinephrine (20 +/- 1 h) groups than the control group (17 +/- 2 h; P < 0.05 vs. other groups), and significantly longer in the combined dopamine-norepinephrine and dobutamine-norepinephrine groups (24 +/- 5 h) than in the norepinephrine alone group (P < 0.05). Histologic examination of lung biopsies revealed less severe lesions in the dobutamine-norepinephrine group than in the control and norepinephrine alone groups. Anatomic alterations in the lung, liver, and small intestine were less severe in the dobutamine-norepinephrine group than in the other groups.
CONCLUSIONS: In this prolonged septic shock model, association of norepinephrine with either dopamine or dobutamine resulted in the longest survival and the least severe pulmonary lesions. The combination of dobutamine with norepinephrine was associated with a better myocardial performance, greater Do(2) and [OV0312]o(2), lower blood lactate concentration and Pco(2) gap, and less anatomic injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657850     DOI: 10.1097/00000542-200304000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  4 in total

1.  Hemodynamic management of septic shock.

Authors:  Daniel De Backer
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

2.  Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study.

Authors:  Glenn Hernandez; Alejandro Bruhn; Cecilia Luengo; Tomas Regueira; Eduardo Kattan; Andrea Fuentealba; Jorge Florez; Ricardo Castro; Andres Aquevedo; Ronald Pairumani; Paul McNab; Can Ince
Journal:  Intensive Care Med       Date:  2013-06-06       Impact factor: 17.440

3.  Vasopressors in shock: too early to move away from catecholamines?

Authors:  D De Backer; S Scolletta
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients.

Authors:  Thomas Schilling; Matthias Gründling; Christof M Strang; Klaus-Uwe Möritz; Werner Siegmund; Thomas Hachenberg
Journal:  Intensive Care Med       Date:  2004-05-11       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.